Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has disclosed its FY2024 preliminary consolidated financial results, reporting revenue of KRW 4.547T (+23.1% YoY) and operating profit of KRW 1.320T (+18.5% YoY).
📊 [Key Disclosure Details & Financial Figures]
- Disclosure Title: Change of 15% or More in Revenue or Profit/Loss Structure (Large-Scale Company)
- Financial Statement Type: Consolidated
- Consolidated Profit/Loss Changes (Unit: KRW, %):
- Revenue: KRW 4,547,322,176,000 (+23.1% YoY)
- Operating Profit: KRW 1,320,052,380,000 (+18.5% YoY)
- Profit Before Income Tax: KRW 1,370,051,626,000 (+22.3% YoY)
- Net Profit: KRW 1,083,315,886,000 (+26.3% YoY)
- Consolidated Financial Position (Unit: KRW):
- Total Assets: KRW 17,336,296,350,000
- Total Liabilities: KRW 6,431,620,287,000
- Total Equity: KRW 10,904,676,062,000
- Capital Stock: KRW 177,935,000,000
- Additional Disclosed Details (Separate Basis):
- Separate Revenue: KRW 3,497,145,676,000
- Main Causes of Change:
- Continued stable operation of Plants 1–3
- Increased revenue contribution from the ramp-up of Plant 4
- Board Resolution Date: January 22, 2025 (4 independent directors present)
- Other Important Details:
- The figures were prepared prior to completion of the external audit and are subject to change depending on audit outcomes.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring Revenue Changes and Upcoming Audit Report Filing
This filing provides Samsung Biologics’ FY2024 preliminary consolidated financial results reflecting changes in its profit/loss structure.
Because these figures were prepared prior to completion of the external audit, checking the finalized numbers in the upcoming audit report is essential.
Relevant details can be verified in subsequent official disclosures regarding audit results.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
